{
    "nct_id": "NCT04340193",
    "official_title": "A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)",
    "inclusion_criteria": "* Participant has intermediate-stage hepatocellular carcinoma (HCC) whose tumor characteristics exceed the Beyond Milan and Up-to-7 (BMU7) criteria and is eligible for trans-arterial ChemoEmbolization (TACE)\n* Participant has no extrahepatic spreading (EHS), no regional lymph node involvement, no main, left main, or right main portal vein thrombosis, and no macrovascular invasion (MVI)\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC\n* Prior liver transplant or participants who are on the waiting list for liver transplantation\n* Active, known, or suspected autoimmune disease\n\nOther protocol defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}